Bronchopulmonary Dysplasia – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Bronchopulmonary Dysplasia – Pipeline Review, H1 2020’, provides an overview of the Bronchopulmonary Dysplasia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia

– The report reviews pipeline therapeutics for Bronchopulmonary Dysplasia by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bronchopulmonary Dysplasia therapeutics and enlists all their major and minor projects

– The report assesses Bronchopulmonary Dysplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advent Therapeutics Inc

Airway Therapeutics LLC

Ayuvis Research Inc

Chiesi Farmaceutici SpA

Insmed Inc

MediPost Co Ltd

Meridigen Biotech Co Ltd

Orphanix GmbH

Radikal Therapeutics Inc

Syntrix Biosystems Inc

Takeda Pharmaceutical Co Ltd

The Cell Factory BVBA

Trimunocor Ltd

United Therapeutics Corp

Windtree Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Bronchopulmonary Dysplasia - Overview

Bronchopulmonary Dysplasia - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Bronchopulmonary Dysplasia - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development

Advent Therapeutics Inc

Airway Therapeutics LLC

Ayuvis Research Inc

Chiesi Farmaceutici SpA

Insmed Inc

MediPost Co Ltd

Meridigen Biotech Co Ltd

Orphanix GmbH

Radikal Therapeutics Inc

Syntrix Biosystems Inc

Takeda Pharmaceutical Co Ltd

The Cell Factory BVBA

Trimunocor Ltd

United Therapeutics Corp

Windtree Therapeutics Inc

Bronchopulmonary Dysplasia - Drug Profiles

Aerosurf - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVR-48 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFMEV-132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Bronchopulmonary Dysplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mecasermin rinfabate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

perfluorooctyl bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pioglitazone + B-YL - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pneumostem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-908 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Surfactant Associated Protein D Replacement for Bronchopulmonary Dysplasia and Lung Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-576 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UNEX-42 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vitamin A palmitate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bronchopulmonary Dysplasia - Dormant Projects

Bronchopulmonary Dysplasia - Discontinued Products

Bronchopulmonary Dysplasia - Product Development Milestones

Featured News & Press Releases

Aug 23, 2019: Medipost’s Pneumostem gets FDA’s fast-track designation

May 15, 2019: Meridigen new Neonatal Stem Cell Drug received TFDA Approval for Clinical Trial

May 09, 2019: New phase 2b analysis suggests AEROSURF may reduce incidence and severity of bronchopulmonary dysplasia in preterm infants with RDS

Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.

Dec 10, 2018: New data from the AEROSURF phase 2b clinical program shows AEROSURF appears to reduce incidence and severity of Bronchopulmonary Dysplasia in preterm infants with RDS

Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia

Aug 24, 2018: Airway Therapeutics announces appointment of chief medical officer

May 03, 2016: MEDIPOST receives US Patent for ‘PNEUMOSTEM’ for Treating Lung Disease

Sep 14, 2014: MediPost America clears Phase 1/2 IND for the U.S. clinical trial on stem cell drug for lung

Aug 12, 2014: MediPost, lung disease stem cell treatment drug 'Pneumostem' application for US clinical trial

Jul 29, 2014: Lung disease stem cell drug designated ‘orphan drug in development stage’

Feb 06, 2014: Stem cells to treat lung disease in preterm infants

Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem

May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Bronchopulmonary Dysplasia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Advent Therapeutics Inc, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Airway Therapeutics LLC, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Ayuvis Research Inc, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Chiesi Farmaceutici SpA, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Insmed Inc, H1 2020

Bronchopulmonary Dysplasia – Pipeline by MediPost Co Ltd, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Meridigen Biotech Co Ltd, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Orphanix GmbH, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Radikal Therapeutics Inc, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Syntrix Biosystems Inc, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Bronchopulmonary Dysplasia – Pipeline by The Cell Factory BVBA, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Trimunocor Ltd, H1 2020

Bronchopulmonary Dysplasia – Pipeline by United Therapeutics Corp, H1 2020

Bronchopulmonary Dysplasia – Pipeline by Windtree Therapeutics Inc, H1 2020

Bronchopulmonary Dysplasia – Dormant Projects, H1 2020

Bronchopulmonary Dysplasia – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Bronchopulmonary Dysplasia, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports